CLL Society in the News

CLL Society in the News

Medical and general news reports frequently feature CLL Society as a trusted information source and an authoritative voice of CLL patients’ concerns. When CLL Society surfaces in the news, we share it here.

FEATURED NEWS

April 22, 2022

Founder Retirement Announcement

This month marks the end of an era at CLL Society. Patty Koffman, our Co-Founder and Communications Director, will begin enjoying a much-deserved retirement in May, following the launch of our new and improved website. We celebrate her many contributions to the CLL patient community and look forward to Patty’s continued engagement as a volunteer advisor as CLL Society moves into the next chapter of our organization’s evolution.

Read the Tribute to Patty Koffman

February 28, 2022

FDA Authorizes Revisions to Evusheld Dosing

If we have learned anything during this pandemic, we have learned that much of our knowledge quickly becomes obsolete. This is because it’s constantly being swept up in the flood tide of new viral mutation and scientific research.

The pandemic has indeed humbled many, including me.

On 2/24/2022, the FDA announced it recommends doubling the dose of Evusheld to protect the immunocompromised better, including those with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) against all variants of SARS-COV-2, the virus that causes COVID-19.

Read more.

ADDITIONAL READING

After nine years of dedicated service to CLL Society, Patty Koffman, co-founder and communications director for CLL Society, will officially retire from her full-time position with CLL Society on April 30. Patty announced this decision to the Board of Directors in May 2021, allowing us ample time to prepare
We lost a CLL friend, advocate, and scholar to COVID-19. I am heartbroken and not sure where to start my personal tribute. Tom Henry was a special person, active in multiple forums, extraordinarily generous in sharing his wisdom as a pharmacist, faith, and hard-earned experience as a CLL patient.